Vitreous concentration of triamcinolone acetonide after a single transseptal depot injection

Ocular Immunology and Inflammation

Volumn 17, Issue 3, 2009, Pages 216-220

  Silva, Paolo S ^a   Singh, Ravinder J ^b   Bakri, Sophie J ^b   Lising, Ramil S ^a   Santiago, Darby E ^a   Uy, Harvey S ^a,c  

^a UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

^b MAYO CLINIC   (United States)

^c Asian Eye Institute   (Philippines)

Author keywords

Corticosteroids; Peribulbar injection; Transseptal injection; Triamcinolone acetonide; Vitreous concentration

Indexed keywords

EYE DROPS; KENACORT 40; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CILIARY DISK; CLINICAL ARTICLE; DIABETIC RETINOPATHY; DRUG HALF LIFE; DRUG TISSUE LEVEL; EALES DISEASE; ENDOPHTHALMITIS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAOCULAR PRESSURE; MALE; MAXIMUM PLASMA CONCENTRATION; PENETRATING TRAUMA; PERFORATING EYE INJURY; POSTOPERATIVE COMPLICATION; PTOSIS; QUANTITATIVE ANALYSIS; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA HOLE; RETINA VEIN OCCLUSION; RETINITIS PIGMENTOSA; RETROBULBAR HEMORRHAGE; SCLERA; SCLERA DISEASE; SIDE EFFECT; SINGLE DRUG DOSE; THICKNESS; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; VITRECTOMY; VITREOUS BODY; VITREOUS BODY DETACHMENT; VITREOUS HEMORRHAGE;

ADULT; AGED; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; GLUCOCORTICOIDS; HUMANS; INJECTIONS; MALE; MIDDLE AGED; ORBIT; TRIAMCINOLONE ACETONIDE; VITREOUS BODY;

EID: 68849129368     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.1080/09273940802687838     Document Type: Article

References (18)

1. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492-513.
2. Jonas JB, Kreissig I, Degenring R. Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases. Prog Retin Eye Res. 2005;24:587-611.
3. Vitale AF, Foster CS. Corticosteroids. In: Vitale AF, Foster CS, eds. Diagnosis and Treatment of Uveitis. Philadelphia, PA: WB Saunders, 2002:142-157.
4. Ferrante P, Ramsey A, Bunce C, Lightman S. Clinical trial to compare efficacy and side-effects of injection of posterior sub-Tenon triamcinolone versus orbital floor methylprednisolone in the management of posterior uveitis. Clin Exp Ophthalmol. 2004;32:563-568.
5. Bakri SJ, Kaiser PK. Posterior subtenon triamcinolone acetonide for refractory diabetic macular edema. Am J Ophthalmol. 2005;139:290-294.
6. Beer PM, Bakri SJ, Singh RJ, et al. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology. 2003;110:681-686.
7. Jonas JB. Intraocular availability of triamcinolone acetonide after intravitreal injection. Am J Ophthalmol. 2004;137:560-562.
8. Mason JO III, Somaiya MD, Singh RJ. Intravitreal concentration and clearance of triamcinolone acetonide in nonvitrectomized human eyes. Retina. 2004;24:900-904.
9. Mueller A, Jian G, Banker AS, et al. The effect of deep posterior subtenon injection of corticosteroids on intraocular pressure. Am J Ophthalmol. 1998;125:158-163.
10. Uy HS, Foster, CS. Diagnostic vitrectomy and intraocular inflammation. Int Ophthalmol Clin. 1999;39:223-235.
11. Singh RJ, Machacek D. Measurement of triamcinolone acetonide by liquid chromatography tandem mass spectrometry (LC-MS/MS). Clin Chem. 2002; 48(6 Suppl):A122.
12. Mclean JM, Gordon DM, Koteen H. Clinical experiences with ACTH and cortisone in ocular diseases. Trans Am Acad Ophthalmol Otolaryngol. 1951;55:565-572.
13. Schimmer BP, Parker KL. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In Brunton LL, Lazo JS, Parker KL, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th ed. New York: McGraw-Hill Professional, 2005:1587-1612.
14. Weijtens O, van der Sluijs FA, Schoemaker RC, et al. Peribulbar corticosteroid injection: vitreal and serum concentrations after dexamethasone disodium phosphate injection. Am J Ophthalmol. 1997;123:358-363.
15. Thomas ER, Wang J, Ege E, et al. Intravitreal triamcinolone acetonide concentration after subtenon injection. Am J Ophthalmol. 2006;142:860-861.
16. Weijtens O, Schoemaker RC, Cohen AF, et al. Dexamethasone concentration in vitreous and serum after oral administration. Am J Ophthalmol. 1998;125:673-679.
17. Freeman WR, Green RL, Smith RE. Echographic localization of corticosteroids after periocular injection. Am J Ophthalmol. 1987;103(3 Pt 1):281-288.
18. Kalina PH, Erie JC, Rosenbaum L. Biochemical quantification of triamcinolone in subconjunctival depots. Arch Ophthalmol. 1995; 113: 867-869.